ImmunoPrecise Antibodies Gets DTC Eligibility For Common Shares

Genetics Investing

ImmunoPrecise Antibodies announced its common shares have been made eligible for book-entry delivery and depository services of The Depository Trust Company to facilitate electronic settlement of transfers of its common shares in the US.

ImmunoPrecise Antibodies (TSXV:IPA; OTCPINK:IPATF) announced its common shares have been made eligible for book-entry delivery and depository services of The Depository Trust Company to facilitate electronic settlement of transfers of its common shares in the US.
As quoted in the press release:

“We are pleased to have obtained DTC eligibility,” said Tom D’Orazio, CEO of ImmunoPrecise. “DTC eligibility simplifies the process of trading and transferring ImmunoPrecise shares between brokerages in the United States and reduces the costs incurred in trading shares. With our shares now DTC eligible, we expect this to lead to greater liquidity and execution speeds, as well as our shares being accessible to an even broader range of investors.”
In addition to the US OTC Market, shares of ImmunoPrecise also continue to trade on the TSX Venture Exchange.

Click here to read the full press release.

Source: www.newswire.ca

immunoprecise antibodies settlement united states us Genetics Investing